Differentiation of metastatic lesions to the bones and multiple myeloma – a case study
Keywordsmultiple myeloma, osteolytic lesions, bones, metastases.
Bones are one of the most common locations for cancer metastasis. Foci, which are in the most cases osteolytic, are located in the spine, ribs, pelvis, long bones. The etiology of changes varies widely as they can be observed in the course of breast, prostate or lung cancer and multiple myeloma.
The aim of the study is to present the case of a 72-year-old female patient after right nephrectomy due to clear cell carcinoma with the presence of disseminated osteolytic foci in the bones located in the ribs, sternum and femur and the existance of calcified pulmonary nodules on diagnostic computed tomography (CT). Basing on the clinical data and imaging results, metastatic bone disease of kidney carcinoma was diagnosed. Despite the treatment, no clinical improvement was observed. In addition, general symptoms such as weakness, weight loss, bone pain appeared. Osteolysis and diffuse osteopenia with hypercalcaemia increased. Further diagnostics – a histopathological examination of the bone marrow combined with laboratory results allowed to make the correct diagnosis - multiple myeloma in stage III in Durie and Salmon classification, in stage 3 according ISS scale. The appropriate treatment was introduced. Patient received bortezomib-thalidomide-dexamethasone chemotherapy regimen and achieved very good partial response (VGPR).
On the grounds of the case given, the key to successful treatment is to carry out detailed differentiation and to make an accurate diagnosis. Coexistence of another cancer should be always considered. A biopsy of pathological lesions is often the only way to diagnose disease.
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12: 6243-6249.
Maccauro G, Spinelli MS, Mauro S, Perisano C, Graci C, Rosa MA. Physiopathology of spine metastasis. Int J Surg Oncol. 2011; 2011: 107969.
Szendroi A, Dinya E, Kardos M, Szász AM, Németh Z, Ats K, Kiss J, Antal I, Romics I, Szendroi M. Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases. Pathol Oncol Res. 2010; 16: 29-38.
Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, Jakovljevic M, Khader Y, Linn S, Lad D, Mantovani L, Nong VM, Mokdad A, Naghavi M, Postma M, Roshandel G, Shackelford K, Sisay M, Nguyen CT, Tran TT, Xuan BT, Ukwaja KN, Vollset SE, Weiderpass E, Libby EN, Fitzmaurice C. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018; 4: 1221-1227.
Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28: iv52-iv61.
Urbanowicz A.: Multiple osteolytic lesions — diagnostic difficulties. Case report. Onkol. Prak. Klin 2012; 8: 155-158.
Ozturk MA, Dane F, Kaygusuz I, Asmaz O, Uzay A, Bayik M, Turhal NS. Synchronous renal cell carcinoma and multiple myeloma: report of two cases and review of the literature. J BUON. 2009; 14: 511-514.
Harmer D, Falank C, Reagan MR. Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma. Front Endocrinol (Lausanne). 2019; 9: 788.
Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015; 125: 1870-1876.
Shahi F, Ghalamkari M, Mirzania M, Khatuni M. A patient with Multiple myeloma and Renal cell carcinoma. Int J Hematol Oncol Stem Cell Res. 2016; 10: 56-60.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 271
Number of citations: 0